Pemigatinib for treating myeloproliferative neoplasms with FGFR1 rearrangement

Pemigatinib is in clinical development for the treatment of adult patients with myeloproliferative neoplasms (MPN) with FGFR1 rearrangement. MPN are types of blood cancers that originate from the bone marrow, and they occur when the bone marrow overproduces one or more types of blood cells. These cells can crowd the bone marrow and reduce its ability to produce enough healthy blood cells. They can also change the thickness of the blood or become abnormal thereby reducing their functionality. MPN with FGFR1 rearrangement are uncommon and extremely aggressive with poor prognosis. Bone marrow or stem cell transplant is a potential curative treatment but may not be suitable for many patients. Other treatments to control symptoms such as chemotherapy are usually less effective, hence the need for more effective targeted treatment.